James Beck, PhD, on Identifying Genetic Variants of Parkinson Disease

Video

The chief scientific officer and senior vice president of the Parkinson’s Foundation discussed mutations the Parkinson’s Foundation has identified.

“What we hope to do by our initiative is not only advanced the potential for precision medicine therapies but change the standard of care for those living with Parkinson's disease.”

The Parkinson’s Foundation is aiming to increase the genetics knowledge base of people with Parkinson disease (PD) as precision medicine and gene therapies grow in prominence and are starting to be explored and tested in more fields with the launce of PDGENEration (NCT04057794).

The Foundation believes genetic counseling and testing for people with PD needs to become part of the standard of care to enable future genetic medicine treatment or participation in clinical trials. Currently, the genetic status of many patients with PD remainsunknown since most have not been genetically tested. Participation in PDGENEration is available at-home or in-person at sites across the US to people with PD.

CGTLive spoke with James Beck, PhD, chief scientific officer and senior vice president, Parkinson’s Foundation, to learn more about the findings that PDGENEration has discovered. Neurologists seeking more information about PD GENEration can visit PDGENEration.com or email [email protected] questions about enrollment.

REFERENCE
Parkinson’s Foundation announces major expansion of PD GENErationstudy, increasing access to genetic testing and counseling across the U.S. News release. Parkinson’s Foundation. May 3, 2022. https://www.parkinson.org/about-us/press-release/Parkinsons-Foundation-expansion-PD-GENEration-study
Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.